Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
58 hedge funds and large institutions have $33.1M invested in Regulus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 19 reducing their positions, and 15 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 19
6.55% less ownership
Funds ownership: 44.43% → 37.88% (-6.5%)
15% less funds holding
Funds holding: 68 → 58 (-10)
37% less capital invested
Capital invested by funds: $52.9M → $33.1M (-$19.8M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
87% less call options, than puts
Call options by funds: $14K | Put options by funds: $107K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.37M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.39M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.34M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$988K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$295K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.5M |
| 2 |
Axa
Paris,
France
|
-$2.4M |
| 3 |
Millennium Management
New York
|
-$847K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$342K |
| 5 |
Renaissance Technologies
New York
|
-$322K |
RGLS Hedge Fund Activity: Q1 2017 in Review
58 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2017, worth a combined $33.1M — down 37% from $52.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RGLS and 9 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 20 added.
The largest buyer was BlackRock, adding an estimated $3.37M. The largest seller was Wellington Management Group, exiting entirely with an estimated $10.5M sold.
- 58 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2017, down from 68 in Q4 2016.
- Funds reported $33.1M of Regulus Therapeutics stock for Q1 2017, down 37% quarter-over-quarter.
- 9 funds opened new Regulus Therapeutics positions in Q1 2017 and 15 closed out, a net change of -6 holders.
- The largest Regulus Therapeutics buyer in Q1 2017 was BlackRock, an estimated $3.37M added.
- The largest Regulus Therapeutics seller in Q1 2017 was Wellington Management Group, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2017.